199 related articles for article (PubMed ID: 33166087)
1. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.
Bastos DC; Ribeiro CF; Ahearn T; Nascimento J; Pakula H; Clohessy J; Mucci L; Roberts T; Zanata SM; Zadra G; Loda M
J Pathol; 2021 Mar; 253(3):292-303. PubMed ID: 33166087
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
3. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
4. Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.
De Piano M; Manuelli V; Zadra G; Otte J; Edqvist PD; Pontén F; Nowinski S; Niaouris A; Grigoriadis A; Loda M; Van Hemelrijck M; Wells CM
Oncogene; 2020 Apr; 39(18):3666-3679. PubMed ID: 32139877
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
Migita T; Ruiz S; Fornari A; Fiorentino M; Priolo C; Zadra G; Inazuka F; Grisanzio C; Palescandolo E; Shin E; Fiore C; Xie W; Kung AL; Febbo PG; Subramanian A; Mucci L; Ma J; Signoretti S; Stampfer M; Hahn WC; Finn S; Loda M
J Natl Cancer Inst; 2009 Apr; 101(7):519-32. PubMed ID: 19318631
[TBL] [Abstract][Full Text] [Related]
6. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
7. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
[TBL] [Abstract][Full Text] [Related]
8. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.
Ahmad I; Mui E; Galbraith L; Patel R; Tan EH; Salji M; Rust AG; Repiscak P; Hedley A; Markert E; Loveridge C; van der Weyden L; Edwards J; Sansom OJ; Adams DJ; Leung HY
Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8290-5. PubMed ID: 27357679
[TBL] [Abstract][Full Text] [Related]
9. Exploring a role for fatty acid synthase in prostate cancer cell migration.
De Piano M; Manuelli V; Zadra G; Loda M; Muir G; Chandra A; Morris J; Van Hemelrijck M; Wells CM
Small GTPases; 2021 Jul; 12(4):265-272. PubMed ID: 33043786
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
11. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.
Liu J; Muturi HT; Khuder SS; Helal RA; Ghadieh HE; Ramakrishnan SK; Kaw MK; Lester SG; Al-Khudhair A; Conran PB; Chin KV; Gatto-Weis C; Najjar SM
Metabolism; 2020 Jun; 107():154215. PubMed ID: 32209360
[TBL] [Abstract][Full Text] [Related]
12. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
13. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
14. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
15. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
16. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
17. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
18. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.
Rodriguez M; Siwko S; Zeng L; Li J; Yi Z; Liu M
Oncogene; 2016 Mar; 35(9):1153-62. PubMed ID: 26028029
[TBL] [Abstract][Full Text] [Related]
20. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
